Secondary progressive multiple sclerosis (SPMS) is diagnosed retrospectively and involves a clinical course characterized by a progressive accumulation of neurological disability, independent of relapses, following an initial relapsing–remitting (RR) phase. Our incomplete understanding of the pathological mechanisms underlying neurodegeneration in multiple sclerosis (MS) may explain why, to date, there is no definitive imaging or laboratory test that is able to inform us when the disease is clearly entering into a progressive phase and why the vast majority of clinical trials testing immunosuppressant and immunomodulating drugs in SPMS patients has so far yielded disappointing or mixed results. Here we discuss the definition(s) of SPMS and how it may vary, outcome measurements (current and emerging) and modern trial design.

Plantone, D., De Angelis, F., Doshi, A., Chataway, J. (2016). Secondary Progressive Multiple Sclerosis: Definition and Measurement. CNS DRUGS, 30, 517-526 [10.1007/s40263-016-0340-9].

Secondary Progressive Multiple Sclerosis: Definition and Measurement

Plantone D
;
2016-01-01

Abstract

Secondary progressive multiple sclerosis (SPMS) is diagnosed retrospectively and involves a clinical course characterized by a progressive accumulation of neurological disability, independent of relapses, following an initial relapsing–remitting (RR) phase. Our incomplete understanding of the pathological mechanisms underlying neurodegeneration in multiple sclerosis (MS) may explain why, to date, there is no definitive imaging or laboratory test that is able to inform us when the disease is clearly entering into a progressive phase and why the vast majority of clinical trials testing immunosuppressant and immunomodulating drugs in SPMS patients has so far yielded disappointing or mixed results. Here we discuss the definition(s) of SPMS and how it may vary, outcome measurements (current and emerging) and modern trial design.
2016
Plantone, D., De Angelis, F., Doshi, A., Chataway, J. (2016). Secondary Progressive Multiple Sclerosis: Definition and Measurement. CNS DRUGS, 30, 517-526 [10.1007/s40263-016-0340-9].
File in questo prodotto:
File Dimensione Formato  
Secondary Progressive Multiple Sclerosis: Definition and Measurement.pdf

accesso aperto

Tipologia: PDF editoriale
Licenza: Creative commons
Dimensione 522.63 kB
Formato Adobe PDF
522.63 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11365/1152716